Literature DB >> 574019

A radioimmunoassay for cytosine arabinoside.

E M Piall, G W Aherne, V M Marks.   

Abstract

A radioimmunoassay (RIA) for cytosine arabinoside (AraC) has been developed using antiserum raised in a sheep to an AraC monophosphate-ovalbumin conjugate. The antibody shows only 0.008% cross-reactivity with uracil arabinoside (AraU) and low (0.023%) cross-reactivity with other commonly co-administered drugs such as cytotoxic and antibacterial agents, and also a number of naturally occurring nucleosides and nucleotides. It does however cross-react by 125% with AraC monophosphate and by 109% with AraC triphosphate. As little as 1 ng/ml of AraC can be detected in plasma, serum, urine and cerebrospinal fluid (CSF) with no need for prior extraction. This RIA has been used to follow the disappearance of AraC from the plasma of patients receiving the drug.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 574019      PMCID： PMC2010074          DOI： 10.1038/bjc.1979.220

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  21 in total

1.  COMPARATIVE STUDIES OF LEUKEMIC CELLS SENSITIVE AND RESISTANT TO CYTOSINE ARABINOSIDE.

Authors:  M Y CHU; G A FISCHER
Journal:  Biochem Pharmacol       Date:  1965-03       Impact factor: 5.858

2.  Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside.

Authors:  R L Momparler; M Y Chu; G A Fischer
Journal:  Biochim Biophys Acta       Date:  1968-07-23

3.  Cytidine deaminase and the development of resistance to arabinosyl cytosine.

Authors:  C D Steuart; P J Burke
Journal:  Nat New Biol       Date:  1971-09-22

4.  Cytosine arabinoside binding to human plasma proteins.

Authors:  H C van Prroijen; G Vierwinden; J Wessels; C Haanen
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-10

5.  Extraction and analytic procedures for cytosine arabinoside and 1-beta-D-arabinofuranosyluracil and their 5'-mono-, di-, and tri-phosphates.

Authors:  W Kreis; C Gordon; C Gizoni; T Woodcock
Journal:  Cancer Treat Rep       Date:  1977-07

6.  A radioimmunoassay for 1-beta-D-arabinofuranosylcytosine.

Authors:  T Okabayashi; S Mihara; D B Repke; J G Moffatt
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

7.  Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 5'-triphosphate of 9-beta-d-arabinofuranoxyladenine.

Authors:  J J Furth; S S Cohen
Journal:  Cancer Res       Date:  1968-10       Impact factor: 12.701

8.  Determination of cytosine arabinoside in human plasma by gas chromatography with a nitrogen-sensitive detector and by gas chromatography--mass spectrometry.

Authors:  J Boutagy; D J Harvey
Journal:  J Chromatogr       Date:  1978-09-01

9.  Radioimmunoassay of bleomycin in plasma and urine.

Authors:  J D Teale; J M Clough; V Marks
Journal:  Br J Cancer       Date:  1977-06       Impact factor: 7.640

10.  Development and application of a radioimmunoassay for methotrexate.

Authors:  G W Aherne; E M Piall; V Marks
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640
View more
  12 in total

1.  Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway.

Authors:  L P Colly; D J Richel; M W Arentsen-Honders; M G Kester; P M ter Riet; R Willemze
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

Review 2.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  A simplified assay for measurement of cytosine arabinoside incorporation into DNA in Ara-C-sensitive and -resistant leukemic cells.

Authors:  L P Colly; D J Richel; W Arentsen-Honders; I W Starrenburg; P M Edelbroek; R Willemze
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.

Authors:  W Kreis; M Lesser; D R Budman; Z Arlin; L DeAngelis; P Baskind; E J Feldman; S Akerman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Subcutaneous infusion of cytosine arabinoside. A practical alternative to intravenous infusion.

Authors:  M L Slevin; E M Piall; G W Aherne; A Johnston; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  A study of the mechanisms of cytotoxicity of Ara-C on three human leukemic cell lines.

Authors:  J Zittoun; J Marquet; J C David; D Maniey; R Zittoun
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside.

Authors:  L M DeAngelis; W Kreis; K Chan; E Dantis; S Akerman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension.

Authors:  M L Slevin; E M Piall; A Johnston; D A Levison; G W Aherne; S B Tree; T A Lister
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

9.  The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.

Authors:  M L Slevin; E M Piall; G W Aherne; A Johnston; M C Sweatman; T A Lister
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

10.  Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study.

Authors:  R A Fleming; R L Capizzi; G L Rosner; L K Oliver; S J Smith; C A Schiffer; R T Silver; B A Peterson; R B Weiss; G A Omura
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.